children and adolescents. Cochrane Database Syst Rev. 2008:CD006279
255) Dong Y, Venketasubramanian N, Chan BP, Sharma VK, Slavin MJ, Collinson SL, Sachdev P, Chan YH, Chen CL. Brief screening tests during acute admission in patients with mild stroke are predictive of vascular cognitive impairment 3-6 months after stroke. Journal of neurology, neurosurgery and psychiatry. 2012;83:580-585
256) Nys GM, van Zandvoort MJ, de Kort PL, van der Worpe HB, Jansen BP, Algra A, de Haan EH, Kappelle LJ. The prognostic value of domain-specific cognitive abilities in acute first-ever stroke. Neurology. 2005;64:821-827
257) Wagle J, Farner L, Flekkøy K, Bruun Wyller T, Sandvik L, Fure B, Stensrød B, Engedal K. Early post-stroke cognition in stroke rehabilitation patients predicts functional outcome at 13 months. Dementia and geriatric cognitive disorders. 2011;31:379-387
258) Barker Collo SL, Feigin VL, Lawes CM, Parag V, Senior H, Rodgers A. Reducing attention deficits after stroke using attention process training: a randomized controlled trial. Stroke. 2009;40:3293-3298
259) Cicerone KD, Langenbahn DM, Braden C, Malec JF, Kalmar K, Fraas M, Felicetti T, Laatsch L, Harley JP, Bergquist T, Azulay J, Cantor J, Ashman T. Evidence-based cognitive rehabilitation: an updated review of the literature from 2003 through 2008. Archives of physical medicine and rehabilitation. 2011;92:519-530
260) Malec JF. Impact of comprehensive day treatment on societal participation for persons with acquired brain injury. Archives of physical medicine and rehabilitation. 2001;82:885-895
261) Rojas Fernandez CH, Moorhouse P. Current concepts in vascular cognitive impairment and pharmacotherapeutic implications. Ann Pharmacother. 2009;43:1310-1323
262) Kavirajan H, Schneider LS. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials. Lancet neurology. 2007;6:782-792
263) Moretti A, Gorini A, Villa RF. Pharmacotherapy and prevention of vascular dementia. CNS & neurological disorders drug targets. 10:370-390
264) Román GC, Salloway S, Black SE, Royall DR, Decarli C, Weiner MW, Moline M, Kumar D, Schindler R, Posner H. Randomized, placebo-controlled, clinical trial of donepezil in vascular dementia: differential effects by hippocampal size. Stroke. 41:1213-1221
265) Kirshner HS. Vascular dementia: a review of recent evidence for prevention and treatment. Current neurology and neuroscience reports. 2009;9:437-442
266) Barrett KM, Brott TG, Brown RD, Carter RE, Geske JR, Graff Radford NR, McNeil RB, Meschia JF. Enhancing recovery after acute ischemic stroke with donepezil as an adjuvant therapy to standard medical care: results of a phase IIA clinical trial. Journal of stroke and cerebrovascular diseases. 20:177-182
267) Wheaton P, Mathias JL, Vink R. Impact of pharmacological treatments on cognitive and
<PAGE>115